Novo Nordisk and Eli Lilly will provide their GLP-1 drugs via President Donald Trump’s direct-to-consumer marketplace for worth $350 per month. The future pills manufactured by industries like Novo’s oral Wegovy or any GLP-1 pill that received approval later will be available at $150 for the initial doses. This deal was confirmed directly from the White House in the presence of Eli Lilly’s Davis Ricks and Novo CEO, Maziar Mike. The live conference was a bit disturbed when one of the attendees, right next to Doustdar, lost his balance.
Following the feed haven’t received the publication but White House informed the reporters that the man was from one of the companies attending the conference, and now he’s okay. Before the feed interruption, Trump’s cabinet officials explained that the deal is a way to support the American population to lose weight and actively serve to their respective productivity accordingly.
The Health Secretary, Robert F. Kennedy Jr., said, “This is the largest drug in our country, so it holds that importance to all the MFN (Most Favored Nation) announcements we’ve mentioned. This will impact millions of Americans.”
This deals with the two popular GLP-1 leaders represent the third MFN drug pricing agreement for the White House to witness after AstraZeneca and Pfizer. In the executive order, the president presented a framework for industries this year to introduce their drug prices aligned with what other identical regions pay.
Officialising the deal White House stated that the price of Wegovy and Ozempic will be cut from $1,350 and $1,000 per month to $350 for either drug through the TrumpRx platform, which is around the corner to ramp next year. Following this, Lilly will provide Zepbound worth $1,086 and the weight loss pill orforglipron at $346 on the platform.
The deal will also lock the $150 price for the future weight loss pills. The fact sheet claims that Novo’s upcoming similar ‘GLP-1’ and Wegovy oral drugs in every company’s portfolio will be worth $150 for the primary doses.
Diabetes version, Mounjaro of Lilly’s tirzepatide franchise, the deal will witness the drug under the Medicare line for $245, the same price as Wegovy, Ozempic and Xepbound in that program. This agreement also secures an extensive coverage for the weight loss drugs for the first time under Medicare.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
